Latigo Biotherapeutics Inc (LTGO)

$22.15 +0.61 (2.83%)
Market Cap 1.47B
Revenue (ttm) 0.00
Net Income (ttm) -109.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 178,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 66.30M
Stochastic %K 26%
Beta N/A
Analysts Strong Sell
Price Target $52.25

Company Profile

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 716 2927
Address:
1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, United States
TopTierNewswire
TopTierNewswire Sep. 4 at 4:36 AM
On watch for me, from the Top Tier Newswire AI model, these names haven't ran yet and are fresh candidates: $SGI $VRNS $ASND $LTGO
0 · Reply
notreload_ai
notreload_ai Sep. 1 at 1:26 PM
Four banks initiate coverage of $LTGO after its IPO, citing LTG-001, 2027 data, and cash runway into 2028 for non-opioid pain drugs. https://notreload.xyz/xy/wall-street-starts-coverage-of-latigo-pain-pipeline/
0 · Reply
IrishHusky
IrishHusky Aug. 26 at 6:16 PM
$LTGO 3rd
0 · Reply
Twenerz
Twenerz Aug. 23 at 3:41 PM
$LTGO
0 · Reply
Ralarco
Ralarco Aug. 22 at 3:07 PM
$LTGO 2nd....?
0 · Reply
eman1200
eman1200 Aug. 14 at 4:15 PM
$LTGO 1st?
0 · Reply
Latest News on LTGO
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Sep 3, 2026, 4:05 PM EDT - 10 days ago

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Latigo Biotherapeutics Earnings release: Q2 2026

Sep 3, 2026, 4:00 PM EDT - 10 days ago

Latigo Biotherapeutics Earnings release: Q2 2026

Latigo Biotherapeutics Quarterly report: Q2 2026

Sep 3, 2026, 4:00 PM EDT - 10 days ago

Latigo Biotherapeutics Quarterly report: Q2 2026

Latigo Biotherapeutics Slides: Corporate presentation

Sep 3, 2026, 7:00 AM EDT - 10 days ago

Latigo Biotherapeutics Slides: Corporate presentation

Latigo Biotherapeutics initiated with a Buy at Jefferies

2026-09-01T10:25:49.000Z - 12 days ago

Latigo Biotherapeutics initiated with a Buy at Jefferies

Latigo Biotherapeutics initiated with an Outperform at Leerink

2026-09-01T10:10:44.000Z - 12 days ago

Latigo Biotherapeutics initiated with an Outperform at Leerink

Latigo Biotherapeutics initiated with a Buy at Guggenheim

2026-09-01T09:25:07.000Z - 13 days ago

Latigo Biotherapeutics initiated with a Buy at Guggenheim

Latigo Biotherapeutics initiated with a Buy at Goldman Sachs

2026-09-01T08:30:07.000Z - 13 days ago

Latigo Biotherapeutics initiated with a Buy at Goldman Sachs

Latigo Biotherapeutics opens at $21, IPO priced at $18 per share

2026-08-07T15:45:33.000Z - 5 weeks ago

Latigo Biotherapeutics opens at $21, IPO priced at $18 per share

Latigo Biotherapeutics indicated to open at $20, IPO priced at $18

2026-08-07T14:11:23.000Z - 5 weeks ago

Latigo Biotherapeutics indicated to open at $20, IPO priced at $18

Latigo Biotherapeutics 19.2M share IPO priced at $18.00

2026-08-07T03:00:35.000Z - 5 weeks ago

Latigo Biotherapeutics 19.2M share IPO priced at $18.00

Latigo Biotherapeutics Registration statement: Registration filing

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

Latigo Biotherapeutics Registration statement: Registration filing

Latigo Biotherapeutics 16M share IPO price range $16.00-$18.00

2026-08-04T09:05:30.000Z - 5 weeks ago

Latigo Biotherapeutics 16M share IPO price range $16.00-$18.00

Latigo, BlossomHill launch US IPOs as biotech listings rebound

Aug 3, 2026, 8:25 AM EDT - 5 weeks ago

Latigo, BlossomHill launch US IPOs as biotech listings rebound

BLSM

Latigo Biotherapeutics Registration statement: Registration filing

Aug 3, 2026, 8:00 AM EDT - 5 weeks ago

Latigo Biotherapeutics Registration statement: Registration filing

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

Jul 29, 2026, 5:08 PM EDT - 6 weeks ago

Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO

Jul 17, 2026, 1:01 PM EDT - 1 month ago

Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO

Latigo Biotherapeutics IPO Registration Document (S-1)

Jul 17, 2026, 12:33 PM EDT - 1 month ago

Latigo Biotherapeutics IPO Registration Document (S-1)

TopTierNewswire
TopTierNewswire Sep. 4 at 4:36 AM
On watch for me, from the Top Tier Newswire AI model, these names haven't ran yet and are fresh candidates: $SGI $VRNS $ASND $LTGO
0 · Reply
notreload_ai
notreload_ai Sep. 1 at 1:26 PM
Four banks initiate coverage of $LTGO after its IPO, citing LTG-001, 2027 data, and cash runway into 2028 for non-opioid pain drugs. https://notreload.xyz/xy/wall-street-starts-coverage-of-latigo-pain-pipeline/
0 · Reply
IrishHusky
IrishHusky Aug. 26 at 6:16 PM
$LTGO 3rd
0 · Reply
Twenerz
Twenerz Aug. 23 at 3:41 PM
$LTGO
0 · Reply
Ralarco
Ralarco Aug. 22 at 3:07 PM
$LTGO 2nd....?
0 · Reply
eman1200
eman1200 Aug. 14 at 4:15 PM
$LTGO 1st?
0 · Reply